Cumulative effects of stress-sensitivity factors on depressive symptoms and suicide risk: A prospective study

Table 1 Demographic and clinical information of patients with major depressive disorders

Items	Overall MDD group (n = 206)	Subgroup based on follow-up data (n = 119)	Sig.
Age (years)	23 (10)	22 (9)	0.132
Years of education	14.52 ± 2.55	14.33 ± 2.66	0.530
BMI (kg/m2)	22.02 ± 4.34	22.43 ± 4.78	0.424
Gender (female), No. (%)	148 (71.8)	87 (73.1)	0.806
Marriage (unmarried), No. (%)	156 (75.7)	94 (79.0)	0.713
Ethnicity (Han), No. (%)	187 (90.8)	109 (91.6)	0.803
History of drinking, No. (%)	39 (18.9)	22 (18.5)	0.983
History of smoking, No. (%)	31 (15.0)	17 (14.3)	0.947
Depressive episodes	2 (1)	2 (1)	0.493
HAMD-17 score at baseline	21.24 ± 5.28	21.94 ± 5.05	0.557
HAMD-17 score at the end of follow-up1	NA	10.88 ± 7.12	< 0.001a
HAMA score at baseline	21.38 ± 7.54	21.51 ± 7.58	0.883
HAMA score at the end of follow-up1	NA	11.69 ± 7.74	< 0.001a
BSSI score at baseline	8.07 ± 7.68	7.57 ± 7.52	0.568
BSSI score at the end of follow-up1 (n = 66)	NA	5.67 ± 7.10	0.004a
SDS score at baseline	18.50 ± 5.96	19.01 ± 6.07	0.466
SDS score at the end of follow-up1	NA	11.91 ± 7.57	< 0.001a
PDQ-5 score at baseline	11.88 ± 3.54	11.69 ± 3.46	0.630
PDQ-5 score at the end of follow-up1	NA	8.27 ± 4.58	< 0.001a
Antidepressants at baseline
SSRIs, No. (%)	66 (32)	43 (36.1)	0.451
SNRIs, No. (%)	20 (9.7)	12 (10.1)	0.913
SARIs, No. (%)	98 (47.6)	62 (52.1)	0.432
Others2, No. (%)	14 (6.8)	7 (5.9)	0.747
Antidepressants at the end of follow-up
SSRIs, No. (%)	NA	67 (32.5)	NA
SNRIs, No. (%)	NA	18 (8.7)	NA
SARIs, No. (%)	NA	86 (41.7)	NA
Others2, No. (%)	NA	21 (17.6)	NA
Neuroticism score at baseline	44.92 ± 5.97	45.05 ± 5.70	0.919
T-AI score at baseline	59.98 ± 7.06	60.15 ± 6.80	0.824
PSS score at baseline	24.76 ± 4.96	24.83 ± 5.28	0.899
S-AI score at baseline	56.64 ± 8.67	56.47 ± 8.06	0.858

^aP < 0.05.

¹Comparison of clinical manifestations between baseline and the end of the 8-week follow-up.

²Others include Noradrenergic and Specific Serotonergic Antidepressants and Norepinephrine-Dopamine Reuptake Inhibitors.

BMI: Body mass index; HAMD-17: 17-item Hamilton Depression Scale; HAMA: Hamilton Anxiety Scale; BSSI: Beck Scale for Suicide Ideation; SDS: Sheehan Disability Scale; PDQ-5: Perceived Deficits Questionnaire five-item version; SSRIs: Selective Serotonin Reuptake Inhibitors; SNRIs: Serotonin-Norepinephrine Reuptake Inhibitors; SARIs: Serotonin Receptor Antagonists and Reuptake Inhibitors; T-AI: Trait Anxiety Inventory of State-Trait Anxiety Inventory; PSS: Perceived Stress Scale; S-AI: State Anxiety Inventory of State-Trait Anxiety Inventory; NA: Not available.